Eun Joo Cho, Moo Hyun Kim, Young-Hak Kim, Kiyuk Chang, Dong-Ju Choi, Woong Chol Kang, Jinho Shin, Seong Hwan Kim, Namho Lee, Jang Won Son, Joon-Hyung Doh, Woo-Shik Kim, Soon Jun Hong, Moo-Yong Rhee, Youngkeun Ahn, Sang-Wook Lim, Seung Pyo Hong, So-Yeon Choi, Min Su Hyon, Jin-Yong Hwang, Kihwan Kwon, Kwang Soo Cha, Sang-Hyun Ihm, Jae-Hwan Lee, Byung-Su Yoo, Hyo-Soo Kim
The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25 mg with telmisartan 80 mg plus amlodipine 5 mg in hypertensive patients. This is a multicenter, double-blind, active-controlled, phase 3, randomized trial. Patients are randomized to triple combination (telmisartan 40 mg/amlodipine 5 mg/chlorthalidone 12.5 mg, TEL/AML/CHTD group) or dual combination (telmisartan 40 mg/amlodipine 5 mg, TEL/AML group) treatment and then dose up titration to TEL 80/AML5/CHTD25mg and TEL80/AML5, respectively...
August 23, 2023: Journal of Clinical Hypertension